
|Videos|March 31, 2022
A Role for Single Agent TKI Therapies in Treating Renal Cell Carcinoma
Oncologists debate whether TKI monotherapy has a place in renal cell carcinoma treatment after the CLEAR trial.
Advertisement
Episodes in this series

Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Zavabresib Earns FDA Orphan Drug Designation in Myelofibrosis
2
New CAR T-Cell Therapy Earns FDA Breakthrough Status in T-Cell Malignancies
3
Median OS Not Yet Reached With New Immunotherapy Combo in 2L Glioblastoma
4
Data Show Potentially Higher Disease Burden Among Male NDMM Population
5














































